Cite
HARVARD Citation
Sermer, D. et al. (n.d.). SAFETY AND EARLY DATA FROM A PHASE II TRIAL OF PEMBROLIZUMAB (PEM) AND ENTINOSTAT (ENT) IN RELAPSED AND REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND FOLLICULAR LYMPHOMA (FL). Hematological oncology. pp. 331-332. [Online].